0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients

Dennis L. Sprecher, MD; Jonathan Abrams, MD; John W. Allen, MD; William F. Keane, MD; Steven G. Chrysant, MD; Henry Ginsberg, MD; Jerome J. Fischer, MD; Brian F. Johnson, MD; Pierre Theroux, MD; and Leonard Jokubaitis, MD
[+] Article and Author Information

From the Center for Cholesterol Research, University of Cincinnati Medical Center, Cincinnati, Ohio; University of New Mexico Hospital, Albuquerque, New Mexico; Heart Inc., The Hospital of the Good Samaritan, Los Angeles, California; Hennepin County Medical Center, Minneapolis, Minnesota; Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma, Oklahoma City, Oklahoma; Columbia University College of Physicians and Surgeons, New York, New York; Diabetes and Glandular Disease Research Center, San Antonio, Texas; University of Massachusetts Medical School, Worcester, Massachusetts; Institut de Cardiologie de Montreal, Montreal, Quebec; Sandoz Research Institute, East Hanover, New Jersey. Requests for Reprints: Dennis L. Sprecher, MD, Center for Cholesterol Research, University of Cincinnati Medical Center, University Hospital, 231 Bethesda Avenue, Mail Location 540, Cincinnati, OH 45267. Acknowledgments: The authors thank Joan Heggland, RN, for data collection, Rachel Neuwirth for analysis, and Martha Hoffmann for manuscript preparation. Grant Support: By Sandoz Pharmaceuticals Corporation, and Sandoz Canada, Inc.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1994;120(7):537-543. doi:10.7326/0003-4819-120-7-199404010-00002
Text Size: A A A

Objective: To compare the low-density lipoprotein (LDL) cholesterol-lowering efficacy of low-dose combinations of cholestyramine and fluvastatin.

Design: Randomized, double-blind, parallel group, placebo-controlled trial with a 24-week double-blind treatment period divided into three phases.

Setting: Office-based clinics.

Patients: Hypercholesterolemic, with LDL cholesterol of 4.14 mmol/L or greater (≥ 160 mg/dL) and plasma triglycerides of 3.39 mmol/L or less (≤ 300 mg/dL). Four hundred sixty patients were screened; 224 patients were randomized into a double-blind treatment period; 203 completed the study; 6 dropped out because of adverse events.

Intervention: Patients were treated with 10 mg or 20 mg of fluvastatin alone, 8 g or 16 g of cholestyramine alone, or combinations of these fluvastatin and cholestyramine dosages (six treatment groups).

Measurements: Changes in lipid variables, particularly LDL cholesterol.

Results: The 10-mg and 20-mg fluvastatin monotherapy groups showed considerable reductions in LDL cholesterol initially (−20.1% [SD, 8.8%] and −20.2% [SD, 10.1%], respectively); these reductions were maintained. Reductions in LDL cholesterol that resulted from the addition of cholestyramine, 8 g/d, to 10 mg of fluvastatin and 20 mg of fluvastatin were greater than those observed with monotherapy (10-mg fluvastatin − [10-mg fluvastatin plus cholestyramine], 9.1%; 95% CI, 3.8% to 14.4%) and 20-mg fluvastatin − [20-mg fluvastatin plus cholestyramine], 11.6%; CI, 6.5% to 16.8%). The increase in cholestyramine dose to 16 g/d in the three combination groups provided only a modest additional response.

Conclusions: Low-density lipoprotein cholesterol reductions of about 25% to 30% can be achieved with low-dose combination therapy with fluvastatin and cholestyramine. The addition of low-dose resin appears to produce greater overall cholesterol reduction than does a simple doubling of the fluvastatin dosage. The low-dose combination treatment was highly successful in achieving the goals of the National Cholesterol Education Program guidelines.

Figures

Grahic Jump Location
Figure 1.
Study design and numbers of patients initially assigned to each treatment group.

Monotherapy groups received either placebo, fluvastatin, 10 mg/d, or fluvastatin, 20 mg/d, throughout the study. In the combined therapy groups, cholestyramine, 8 mg/d, was added in phase 2 and the dose increased to 16 mg/d in phase 3. CME = cholestyramine; FL = fluvastatin.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Mean low-density lipoprotein cholesterol values in the combination therapy groups during the course of the study.

In phase 1 (weeks 1 to 8), each group showed reductions in mean low-density lipoprotein (LDL) cholesterol similar to those seen in the monotherapy group receiving the same treatment. Increased LDL cholesterol reductions were seen with the addition of cholestyramine, 8 g/d, in phase 2 (weeks 9 to 16), and modest additional reductions occurred when the dose was increased to 16 g/d in phase 3 (weeks 17 to 24).

Grahic Jump Location
Grahic Jump Location
Figure 3.
Percentage of patients in each treatment group achieving low-density lipoprotein cholesterol levels less than 4.

14 mmol/L (<160 mg/dL) at study end point. End-point analysis includes last available lipid measurements for patients who did not complete the study. The highest proportions of patients achieving National Cholesterol Education Program guidelines (low-density lipoprotein cholesterol < 4.41 mmol/L [<160 mg/dL]) were in the combination therapy groups.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)